Jódar E, Romera I, Wang Q, et al. - By conducting post hoc analyses, data were pooled from randomized, phase 3 studies (n=6) assessing the relationship between treatment with dulaglutide 1.5 mg once weekly and glycaemic variability (GV) in adult patients with type 2 diabetes mellitus (T2D).

• Dulaglutide for T2D administered as monotherapy or added to oral glucose-lowering medication, without concomitant insulin treatment, was found to be potentially linked with a decrease in GV.

• A reduction in GV to a greater degree was achieved with dulaglutide vs insulin glargine.

• When added to insulin glargine, dulaglutide treatment was shown to be related to greater reductions in GV than insulin glargine alone.

• Observations from this study may be clinically relevant as decreased GV may be linked with better outcomes.